Dabrafenib mesylate

{
  "id": "MLC-T-ONC-002261",
  "term": "Dabrafenib mesylate",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used alone or with trametinib to treat low-grade glioma (a type of brain tumor) in children aged 1 year and older and certain types of anaplastic thyroid cancer, non-small cell lung cancer, melanoma, and other solid tumors that have a certain mutation (change) in the BRAF gene. It is also being studied in the treatment of other types of cancer. Dabrafenib mesylate blocks certain proteins made by the mutated BRAF gene, which may help keep cancer cells from growing. It is a type of kinase inhibitor. Also called Tafinlar.",
    "The mesylate salt form of dabrafenib, an orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity. Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. B-raf belongs to the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which may be constitutively activated due to BRAF gene mutations."
  ],
  "synonyms": [
    "Tafinlar",
    "GSK2118436B",
    "dabrafenib methanesulfonate",
    "GSK2118436 methane sulfonate salt"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/dabrafenib-mesylate/"
}